Volastertib BI-6727 CAS:755038-65-4 is a novel, potent and selective Polo-like kinase 1 (PLK-1) inhibitor. It has a chemical name (Z)-N'-(3-chloro-4-fluorobenzylidene)-2-(2,6-difluorobenzyl)-1H-pyrrolo[3,2-d]pyrimidine-4,6-diamine. The molecular formula for Volasertib is C26H19ClF3N5 and the molecular weight is 505.91 g/mol. The CAS No for Volasertib is 755038-65-4. Volasertib is a highly active, low molecular weight kinase inhibitor with the potential for the treatment of multiple human cancer types.
Top ten keywords for Volasertib include:
Synonyms for Volasertib include BI6727, BI-6727, and (Z)-N'-(3-chloro-4-fluorobenzylidene)-2-(2,6-difluorobenzyl)-1H-pyrrolo[3,2-d]pyrimidine-4,6-diamine.
Volstertib has been shown to have various potential health benefits. It works by selectively inhibiting the kinase activity of PLK-1, a key regulator of the cell cycle, to cause mitotic arrest and cell death. This makes it effective in reducing tumor growth in various cancer types like solid tumors, ovarian, lung, bladder, breast, and hematological malignancies. Volasertib has been shown to have activity against cancer cells that have acquired resistance to other chemotherapeutic agents. Volasertib induces apoptosis in cells that are not responding to conventional chemotherapy, making it a valuable alternative for cancer treatment.
Studies have also revealed that Volasertib has a unique mechanism of action, different from other PLK-1 inhibitors, making it a possible candidate for combination therapy with other anticancer drugs. Additionally, preclinical studies have reported that Volasertib enhances the effects of radiotherapy.
The safety profile of Volasertib is well established in several clinical trials. In phase I clinical trials, single-dose and multiple doses of Volasertib demonstrated acceptable tolerability with the most common adverse effects being reversible neutropenia and thrombocytopenia, as well as other mild to moderate side effects like nausea, vomiting, and fatigue. The side effects of Volasertib are generally mild and reversible and can be managed with standard supportive measures.
The dosing information for Volasertib varies depending on the type of cancer being treated, and the patient's age and health status. However, the recommended dose is 350 mg/m2 administered once weekly over 60 minutes in a 21-day cycle. Dosage adjustments may be necessary for patients with hepatic impairment.
In conclusion, Volasertib BI-6727 CAS:755038-65-4 is a promising anti-cancer drug that has been effective in treating various cancer types. It works by selectively inhibiting the kinase activity of PLK-1, causing mitotic arrest and cell death. Volasertib has a well-established safety profile, and the side effects are generally mild and reversible. The dosing information varies depending on the type of cancer being treated and the patient's health status. Volasertib's unique mechanism of action and potential for combination therapy makes it a valuable alternative for cancer treatment.
